RxSight price target lowered to $8 from $16 at UBS

UBS lowered the firm’s price target on RxSight (RXST) to $8 from $16 and keeps a Neutral rating on the shares following the Q2 earnings report. RxSight’s commercial strategy pivot is still under way, and its turnaround depends on improving execution, the analyst tells investors in a research note. The firm lacks conviction in raising assumptions, and needs to see evidence that a turnaround is occurring.